Search Results - "BLUM, Joanne L"

Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology) by Blum, Joanne L, Flynn, Patrick J, Yothers, Greg, Asmar, Lina, Geyer, Jr, Charles E, Jacobs, Samuel A, Robert, Nicholas J, Hopkins, Judith O, O'Shaughnessy, Joyce A, Dang, Chau T, Gómez, Henry Leonidas, Fehrenbacher, Louis, Vukelja, Svetislava J, Lyss, Alan P, Paul, Devchand, Brufsky, Adam M, Jeong, Jong-Hyeon, Colangelo, Linda H, Swain, Sandra M, Mamounas, Eleftherios P, Jones, Stephen E, Wolmark, Norman

“…Purpose Docetaxel and cyclophosphamide (TC) was superior to doxorubicin and cyclophosphamide (AC) in a trial in early breast cancer. However, activity of TC…”
Get full text

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study by Cortes, Javier, MD, O'Shaughnessy, Joyce, MD, Loesch, David, MD, Blum, Joanne L, MD, Vahdat, Linda T, MD, Petrakova, Katarina, MD, Chollet, Philippe, MD, Manikas, Alexey, MD, Diéras, Veronique, MD, Delozier, Thierry, MD, Vladimirov, Vladimir, MD, Cardoso, Fatima, MD, Koh, Han, MD, Bougnoux, Philippe, MD, Dutcus, Corina E, MD, Seegobin, Seth, MSc, Mir, Denis, MSc, Meneses, Nicole, MSHS, Wanders, Jantien, MD, Twelves, Chris, Prof

“…Summary Background Treatments with survival benefit are greatly needed for women with heavily pretreated metastatic breast cancer. Eribulin mesilate is a…”
Get full text

Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer by LIN, Nancy U, DIERAS, Véronique, LOIBL, Sibylle, GORI, Stefania, WARDLEY, Andrew, YARDLEY, Denise, BRUFSKY, Adam, BLUM, Joanne L, RUBIN, Stephen D, DHARAN, Bernie, STEPLEWSKI, Klaudia, ZEMBRYKI, Denise, PAUL, Devchand, OLIVA, Cristina, ROYCHOWDHURY, Debasish, PAOLETTI, Paolo, WINER, Eric P, LOSSIGNOL, Dominique, CHRISTODOULOU, Christos, STEMMLER, Hans-Joachim, ROCHE, Henri, LIU, Minetta C, GREIL, Richard, CIRUELOS, Eva

“…Purpose: Brain metastases develop in one third of patients with advanced HER2+ breast cancer. Effective therapy for patients with central nervous system (CNS)…”
Get full text

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735 by JONES, Stephen, HOLMES, Frankie Ann, HYMAN, William J, RICHARDS, Donald A, MENNEL, Robert G, BOEHM, Kristi A, MEYER, Wally G, ASMAR, Lina, MACKEY, Daniel, RIEDEL, Stefan, MUSS, Hyman, SAVIN, Michael A, O'SHAUGHNESSY, Joyce, BLUM, Joanne L, VUKELJA, Svetislava J, MCINTYRE, Kristi J, PIPPEN, John E, BORDELON, James H, KIRBY, Robert L, SANDBACH, John

“…We previously reported that four cycles of docetaxel/cyclophosphamide (TC) produced superior disease-free survival (DFS) compared with four cycles of…”
Get full text

Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study by KAUFF, Noah D, DOMCHEK, Susan M, NEUHAUSEN, Susan L, DALY, Mary B, MATLOFF, Ellen, BLUM, Joanne L, SABBATINI, Paul, BARAKAT, Richard R, HUDIS, Clifford, NORTON, Larry, OFFIT, Kenneth, REBBECK, Timothy R, FRIEBEL, Tara M, ROBSON, Mark E, LEE, Johanna, GARBER, Judy E, ISAACS, Claudine, EVANS, D. Gareth, LYNCH, Henry, EELES, Rosalind A

“…Risk-reducing salpingo-oophorectomy (RRSO) has been widely adopted as a key component of breast and gynecologic cancer risk-reduction for women with BRCA1 and…”
Get full text

Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine by Cortes, Javier, Vahdat, Linda, Blum, Joanne L, Twelves, Chris, Campone, Mario, Roché, Henri, Bachelot, Thomas, Awada, Ahmad, Paridaens, Robert, Goncalves, Anthony, Shuster, Dale E, Wanders, Jantien, Fang, Fang, Gurnani, Renuka, Richmond, Elaine, Cole, Patricia E, Ashworth, Simon, Allison, Mary Ann

“…The activity and safety of eribulin mesylate (E7389), a nontaxane microtubule dynamics inhibitor with a novel mechanism of action, were evaluated in patients…”
Get full text

Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ by Ding, Lina, Su, Ying, Fassl, Anne, Hinohara, Kunihiko, Qiu, Xintao, Harper, Nicholas W., Huh, Sung Jin, Bloushtain-Qimron, Noga, Jovanović, Bojana, Ekram, Muhammad, Zi, Xiaoyuan, Hines, William C., Alečković, Maša, Gil del Alcazar, Carlos, Caulfield, Ryan J., Bonal, Dennis M., Nguyen, Quang-De, Merino, Vanessa F., Choudhury, Sibgat, Ethington, Gabrielle, Panos, Laura, Grant, Michael, Herlihy, William, Au, Alfred, Rosson, Gedge D., Argani, Pedram, Richardson, Andrea L., Dillon, Deborah, Allred, D. Craig, Babski, Kirsten, Kim, Elizabeth Min Hui, McDonnell, Charles H., Wagner, Jon, Rowberry, Ron, Bobolis, Kristie, Kleer, Celina G., Hwang, E. Shelley, Blum, Joanne L., Cristea, Simona, Sicinski, Piotr, Fan, Rong, Long, Henry W., Sukumar, Saraswati, Park, So Yeon, Garber, Judy E., Bissell, Mina, Yao, Jun, Polyak, Kornelia

“…Myoepithelial cells play key roles in normal mammary gland development and in limiting pre-invasive to invasive breast tumor progression, yet their…”
Get full text

Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer by JONES, Stephen E, SAVIN, Michael A, SANDBACH, John, HYMAN, William J, KHANDELWAL, Pankaj, NEGRON, Angel G, RICHARDS, Donald A, ANTHONY, Stephen P, MENNEL, Robert G, BOEHM, Kristi A, MEYER, Walter G, ASMAR, Lina, HOLMES, Frankie Ann, O'SHAUGHNESSY, Joyce A, BLUM, Joanne L, VUKELJA, Svetislava, MCINTYRE, Kristi J, PIPPEN, John E, BORDELON, James H, KIRBY, Robert

“…The combination of doxorubicin and cyclophosphamide (AC) is a standard adjuvant chemotherapy regimen. Studies of docetaxel and cyclophosphamide (TC) in…”
Get full text

Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane by VAHDAT, Linda T, PRUITT, Brian, SMITH, John, O'SHAUGHNESSY, Joyce, SHUSTER, Dale E, MENESES, Nicole L, CHANDRAWANSA, Kumari, FANG FANG, COLE, Patricia E, ASHWORTH, Simon, BLUM, Joanne L, FABIAN, Carol J, RIVERA, Ragene R, SMITH, David A, TAN-CHIU, Elizabeth, WRIGHT, Jonathan, TAN, Antoinette R, DACOSTA, NoshirA, CHUANG, Ellen

“…Eribulin mesylate (E7389), a nontaxane microtubule dynamics inhibitor, is a structurally simplified, synthetic analog of the marine natural product…”
Get full text

Evolutionary pathways in BRCA1-associated breast tumors by Martins, Filipe C, De, Subhajyoti, Almendro, Vanessa, Gönen, Mithat, Park, So Yeon, Blum, Joanne L, Herlihy, William, Ethington, Gabrielle, Schnitt, Stuart J, Tung, Nadine, Garber, Judy E, Fetten, Katharina, Michor, Franziska, Polyak, Kornelia

“…BRCA1-associated breast tumors display loss of BRCA1 and frequent somatic mutations of PTEN and TP53. Here we describe the analysis of BRCA1, PTEN, and p53 at…”
Get more information

Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers by Chai, Xinglei, Friebel, Tara M., Singer, Christian F., Evans, D. Gareth, Lynch, Henry T., Isaacs, Claudine, Garber, Judy E., Neuhausen, Susan L., Matloff, Ellen, Eeles, Rosalind, Tung, Nadine, Weitzel, Jeffrey N., Couch, Fergus J., Hulick, Peter J., Ganz, Patricia A., Daly, Mary B., Olopade, Olufunmilayo I., Tomlinson, Gail, Blum, Joanne L., Domchek, Susan M., Chen, Jinbo, Rebbeck, Timothy R.

“…Inherited mutations in BRCA1 or BRCA2 ( BRCA1/2 ) confer very high risk of breast and ovarian cancers. Genetic testing and counseling can reduce risk and death…”
Get full text

Molecular Profiling of Human Mammary Gland Links Breast Cancer Risk to a p27+ Cell Population with Progenitor Characteristics by Choudhury, Sibgat, Almendro, Vanessa, Merino, Vanessa F., Wu, Zhenhua, Maruyama, Reo, Su, Ying, Martins, Filipe C., Fackler, Mary Jo, Bessarabova, Marina, Kowalczyk, Adam, Conway, Thomas, Beresford-Smith, Bryan, Macintyre, Geoff, Cheng, Yu-Kang, Lopez-Bujanda, Zoila, Kaspi, Antony, Hu, Rong, Robens, Judith, Nikolskaya, Tatiana, Haakensen, Vilde D., Schnitt, Stuart J., Argani, Pedram, Ethington, Gabrielle, Panos, Laura, Grant, Michael, Clark, Jason, Herlihy, William, Lin, S. Joyce, Chew, Grace, Thompson, Erik W., Greene-Colozzi, April, Richardson, Andrea L., Rosson, Gedge D., Pike, Malcolm, Garber, Judy E., Nikolsky, Yuri, Blum, Joanne L., Au, Alfred, Hwang, E. Shelley, Tamimi, Rulla M., Michor, Franziska, Haviv, Izhak, Liu, X. Shirley, Sukumar, Saraswati, Polyak, Kornelia

“…Early full-term pregnancy is one of the most effective natural protections against breast cancer. To investigate this effect, we have characterized the global…”
Get full text

Multicenter, Phase II study of capecitabine in taxane‐pretreated metastatic breast carcinoma patients by Blum, Joanne L., Dieras, Véronique, Lo Russo, Patricia Mucci, Horton, John, Rutman, Olga, Buzdar, Aman, Osterwalder, Bruno

“…BACKGROUND Capecitabine is an oral, tumor‐targeted fluoropyrimidine carbamate with high activity in metastatic breast carcinoma and in paclitaxel‐pretreated…”
Get full text

Dose-Adjusting Capecitabine Minimizes Adverse Effects While Maintaining Efficacy: A Retrospective Review of Capecitabine for Metastatic Breast Cancer by Leonard, Robert, Hennessy, Bryan T, Blum, Joanne L, O'Shaughnessy, Joyce

“…Abstract Capecitabine monotherapy is considered standard treatment in anthracycline- and taxane-pretreated metastatic breast cancer and has proven efficacy in…”
Get full text

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation by Litton, Jennifer K, Rugo, Hope S, Ettl, Johannes, Hurvitz, Sara A, Gonçalves, Anthony, Lee, Kyung-Hun, Fehrenbacher, Louis, Yerushalmi, Rinat, Mina, Lida A, Martin, Miguel, Roché, Henri, Im, Young-Hyuck, Quek, Ruben G.W, Markova, Denka, Tudor, Iulia C, Hannah, Alison L, Eiermann, Wolfgang, Blum, Joanne L

“…Among patients with breast cancer and germline mutations in the BRCA DNA repair pathway genes, the poly(adenosine diphosphate–ribose) inhibitor talazoparib…”
Get full text

Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients by Paul, Devchand, Vukelja, Svetislava J., Ann Holmes, Frankie, Blum, Joanne L., McIntyre, Kristi J., Lindquist, Deborah L., Osborne, Cynthia R., Sanchez, Ines J., Goldschmidt, Jerome H., Wang, Yunfei, Asmar, Lina, Strauss, Lewis, O’Shaughnessy, Joyce

“…The non-receptor tyrosine kinase Src activation plays a role in the malignant progression of breast cancer, including development of endocrine therapy…”
Get full text

Comparison of Menopausal Symptoms During the First Year of Adjuvant Therapy With Either Exemestane or Tamoxifen in Early Breast Cancer: Report of a Tamoxifen Exemestane Adjuvant Multicenter Trial Substudy by JONES, Stephen E, CANTRELL, James, RIVERA, Ragene, HOLMES, Frankie Ann, CHITTOOR, Sreeni, WHITTAKER, Thomas L, BORDELON, James H, KETCHEL, Steven J, DAVIS, Jennifer C, ILEGBODU, Des, KOCHIS, Jean, ASMAR, Lina, VUKELJA, Svetislava, PIPPEN, John, O'SHAUGHNESSY, Joyce, BLUM, Joanne L, BROOKS, Robert, HARTUNG, Nicole L, NEGRON, Angel G, RICHARDS, Donald A

“…Hormonal breast cancer treatment increases menopausal symptoms in women. This study investigated differences between the symptoms associated with either…”
Get full text

Phase II Trial of Capecitabine and Weekly Paclitaxel As First-Line Therapy for Metastatic Breast Cancer by BLUM, Joanne L, DEES, E. Claire, ILEGBODU, Des, BOEHM, Kristi A, ASMAR, Lina, O'SHAUGHNESSY, Joyce A, CHACKO, Aparna, DOANE, Lisa, ETHIRAJAN, Sukumar, HOPKINS, Judith, MCMAHON, Richard, MERTEN, Suzan, NEGRON, Angel, NEUBAUER, Marcus

“…The taxanes and capecitabine have synergistic antitumor activity in preclinical models. This trial was designed to determine the efficacy and tolerability of…”
Get full text

On grief, ghosts, and gallantry by Blum, Joanne L.

Get full text

Talazoparib in Patients with a Germline BRCA‐Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial by Hurvitz, Sara A., Gonçalves, Anthony, Rugo, Hope S., Lee, Kyung‐Hun, Fehrenbacher, Louis, Mina, Lida A., Diab, Sami, Blum, Joanne L., Chakrabarti, Jayeta, Elmeliegy, Mohamed, DeAnnuntis, Liza, Gauthier, Eric, Czibere, Akos, Tudor, Iulia Cristina, Quek, Ruben G.W., Litton, Jennifer K., Ettl, Johannes

“…Background In the EMBRACA phase III study (NCT01945775), talazoparib was associated with a significantly prolonged progression‐free survival (PFS) compared…”
Get full text